Mga Batayang Estadistika
| LEI | 549300XD2PHUC73HMY31 |
| CIK | 1095981 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Plus Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission |
|
| August 22, 2025 |
PLUS THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN Stock Unit Agreement EX-99.2 Exhibit 99.2 PLUS THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN Stock Unit Agreement This Stock Unit Agreement and the associated grant award information (the “Customizing Information”), which Customizing Information is provided in written form or is available in electronic form from the recordkeeper for the Plus Therapeutics, Inc. 2020 Stock Incentive Plan, as amended and in effect from ti |
|
| August 22, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 PLUS THERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Shares, par value $0.001 per share Other 20,075,000 $ 0.49 $ 9,836,750.00 0.0001531 $ 1,506.01 Total O |
|
| August 22, 2025 |
As filed with the Securities and Exchange Commission on August 22, 2025 S-8 As filed with the Securities and Exchange Commission on August 22, 2025 Registration No. |
|
| August 15, 2025 |
PROSPECTUS 33,000,000 Shares of Common Stock 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-289526 PROSPECTUS 33,000,000 Shares of Common Stock This prospectus relates to the offer and sale of up to 33,000,000 shares of our common stock, par value $0.001 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock to wh |
|
| August 14, 2025 |
PLUS THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN EXHIBIT 10.15 PLUS THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN SECTION 1 ESTABLISHMENT AND PURPOSE. (a) The Plan was adopted by the Board of Directors on April 30, 2020 and approved by the Company’s stockholders on June 16, 2020. The Plan was amended and restated by the Board of Directors on March 22, 2021, subject to approval of the Company’s stockholders, which approval occurred on May 17, 202 |
|
| August 14, 2025 |
Exhibit 99.1 Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Texas, August 14, 2025 (GLOBE NEWSWIRE) – Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical compa |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2025 |
EX-99.1 Exhibit 99.1 The unaudited pro forma balance sheet has been filed in order to show compliance with the Nasdaq requirement that the Company maintain a minimum stockholders’ equity of $2.5 million for continued listing. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respe |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAP |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2025 |
Calculation of Filing Fee Tables S-1 PLUS THERAPEUTICS, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Ini |
|
| August 12, 2025 |
EX-10.41 Exhibit 10.41 July 11, 2025 Plus Therapeutics, Inc. 2710 Reed Rd, Suite 160 Houston, TX 77051 Re: Letter of Support (this “Agreement”) Ladies and Gentlemen: Reference is made to that certain letter agreement, dated as of June 17, 2025 (the “Side Letter”), by and among Plus Therapeutics, Inc. (the “Company”) and each of the other parties party thereto (each, an “Investor” and collectively, |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2025 |
As filed with the Securities and Exchange Commission on August 12, 2025. S-1 Table of Contents As filed with the Securities and Exchange Commission on August 12, 2025. |
|
| August 4, 2025 |
DRS Table of Contents Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the U.S. Securities and Exchange Commission on August 1, 2025. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 3 |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 25, 2025 |
PLUS THERAPEUTICS, INC. 2710 Reed Road, Suite 160 Houston, Texas 77051 RW PLUS THERAPEUTICS, INC. 2710 Reed Road, Suite 160 Houston, Texas 77051 July 25, 2025 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-282507) Request for Withdrawal of Registration Statement Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-3 (F |
|
| July 21, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission F |
|
| July 18, 2025 |
Letter from BDO USA, P.C. to the Securities and Exchange Commission dated July 18, 2025 Exhibit 16.1 July 18, 2025 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on July 16, 2025, to be filed by our former client, Plus Therapeutics, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, /s/ |
|
| July 11, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| June 23, 2025 |
PROSPECTUS 17,000,000 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-288121 PROSPECTUS 17,000,000 Shares of Common Stock This prospectus relates to the offer and sale of up to 17,000,000 shares of our common stock, par value $0.001 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock to wh |
|
| June 23, 2025 |
PLUS THERAPEUTICS, INC. 2710 Reed Road, Suite 160 Houston, Texas 77051 RW PLUS THERAPEUTICS, INC. 2710 Reed Road, Suite 160 Houston, Texas 77051 June 23, 2025 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-286393) Request for Withdrawal of Registration Statement Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-3 (File |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 18, 2025. S-1/A Table of Contents As filed with the Securities and Exchange Commission on June 18, 2025. |
|
| June 20, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 17, 2025, by and between PLUS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have t |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission F |
|
| June 20, 2025 |
Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of June 17, 2025, by and between PLUS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined are defined in Section 1 of this Agreement. WHEREAS: Subject to the terms a |
|
| June 18, 2025 |
Exhibit 10.38 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of June 17, 2025, by and between PLUS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined are defined in Section 1 of this Agreement. WHEREAS: Subject to the terms |
|
| June 18, 2025 |
Exhibit 10.39 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 17, 2025, by and between PLUS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have |
|
| June 18, 2025 |
As filed with the Securities and Exchange Commission on June 17, 2025. S-1 Table of Contents As filed with the Securities and Exchange Commission on June 17, 2025. |
|
| June 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Plus Therapeutics, Inc. |
|
| June 17, 2025 |
June 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 submitted for filing on June 17, 2025 File No. 333- Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securiti |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission F |
|
| June 17, 2025 |
Exhibit 10.1 June 17, 2025 Plus Therapeutics, Inc. 4200 Marathon Blvd., Suite 200 Austin, Texas 78756 Re: Letter Agreement (this “Agreement”) Ladies and Gentlemen: Reference is made to that certain Securities Purchase Agreement, dated as of March 4, 2025 (the “Purchase Agreement”), by and among Plus Therapeutics, Inc. (the “Company”) and each of the other parties party thereto (each, an “Investor” |
|
| June 17, 2025 |
Form of Amended and Restated Series B Common Stock Purchase Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 9, 2025 |
Table of Contents Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the U.S. Securities and Exchange Commission on June 9, 2025 This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERA |
|
| May 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 30, 2025 |
Exhibit 99.1 Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, Texas, May 30, 2025 (GLOBE NEWSWIRE) – Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted |
|
| May 23, 2025 |
Exhibit 99.1 Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q Houston, TX | May 23, 2025 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated that the Company was not in compliance with Nasdaq Listing Rule 525 |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 19, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 15, 2025 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: . . . . . 3235-0058 Washington, D.C. 20549 Expires: May 31, 2025 Estimated average burden hours FORM 12b-25 per response. . . . . . . . 2.50 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34375 CUSIP NUMBER 72941H509 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Perio |
|
| May 2, 2025 |
Certificate of Amendment to the Certificate of Incorporation, as amended Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PLUS THERAPEUTICS, INC. Plus Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: The name of the corporation is Plus Therapeutics, Inc. (the “Corporation”). SECOND: On March 4 2025, the Board of Di |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34375 (Commission File Number) 3 |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-3 |
|
| April 23, 2025 |
EX-24.2 Exhibit 24.2 PLUS THERAPEUTICS, INC. POWER OF ATTORNEY The undersigned director of Plus Therapeutics, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Marc H. Hedrick, M.D., and Andrew Sims, and each of them, with full power of substitution and resubstitution and full power to act without the other, his true and lawful attorney-in-fact and agent to act in su |
|
| April 23, 2025 |
As filed with the Securities and Exchange Commission on April 23, 2025 S-3/A Table of Contents As filed with the Securities and Exchange Commission on April 23, 2025 Registration No. |
|
| April 18, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280061 PROSPECTUS SUPPLEMENT NO. 9 (To Prospectus dated June 24, 2024) Plus Therapeutics, Inc. This prospectus supplement updates and supplements the prospectus, dated June 24, 2024 (as supplemented to date, the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280061). This prospectus supplement is being file |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34375 (Commission File Number |
|
| April 11, 2025 |
As filed with the Securities and Exchange Commission on April 11, 2025 Table of Contents As filed with the Securities and Exchange Commission on April 11, 2025 Registration No. |
|
| April 10, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ D |
|
| April 4, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Plus Therapeutics, Inc. |
|
| April 4, 2025 |
Exhibit 24.1 PLUS THERAPEUTICS, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Plus Therapeutics, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Marc H. Hedrick, M.D., and Andrew Sims, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fact a |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 4, 2025 Registration No. |
|
| April 1, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 1, 2025 |
Hogan Lovells US LLP Harbor East 100 International Drive Suite 2000 Baltimore, MD 21202 T +1 410 659 2700 F +1 410 659 2701 www. |
|
| March 31, 2025 |
PLUS THERAPEUTICS, INC. 2710 Reed Road, Suite 160 Houston, Texas 77051 PLUS THERAPEUTICS, INC. 2710 Reed Road, Suite 160 Houston, Texas 77051 March 31, 2025 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-275712) Request for Withdrawal of Registration Statement Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-1 (File No |
|
| March 31, 2025 |
Exhibit 19 PLUS THERAPEUTICS, INC. INSIDER TRADING AND COMMUNICATIONS POLICY Policy as to Trades in the Company’s Securities By Company Personnel and Treatment of Confidential Information 1. Purpose. Both the Securities and Exchange Commission (the “SEC”) and Congress are very concerned about maintaining the fairness and integrity of the U.S. capital markets. The securities laws are continually re |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTI |
|
| March 31, 2025 |
Exhibit 21 List of Subsidiaries of the Registrant Wholly Owned Subsidiary Place of Incorporation CNSide Diagnostics, LLC Delaware |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 27, 2025 |
Exhibit 99.1 Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights The recent $15 million financing accelerates development of REYOBIQ™ and launch of CNSide™ HOUSTON, Texas, March 27, 2025 (GLOBE NEWSWIRE) – Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics wit |
|
| March 14, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 PLUS THERAPUETICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission F |
|
| March 10, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-280061 PROSPECTUS SUPPLEMENT NO. 8 (To Prospectus dated June 24, 2024) Plus Therapeutics Inc. This prospectus supplement updates and supplements the prospectus, dated June 24, 2024 (as supplemented to date, the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280061). This prospectus supplement is being |
|
| March 4, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-280061 PROSPECTUS SUPPLEMENT NO. 7 (To Prospectus dated June 24, 2024) Plus Therapeutics Inc. This prospectus supplement updates and supplements the prospectus, dated June 24, 2024 (as supplemented to date, the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280061). This prospectus supplement is being |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 PLUS THERAPUETICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission F |
|
| March 4, 2025 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| March 4, 2025 |
Form of Securities Purchase Agreement, dated as of March 4, 2025 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 4, 2025, by and among Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an |
|
| March 4, 2025 |
EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| March 4, 2025 |
Form of First Amendment to Securities Purchase and Exchange Agreement, dated as of March 4, 2025 EX-10.3 Exhibit 10.3 FIRST AMENDMENT TO SECURITIES PURCHASE AND EXCHANGE AGREEMENT This FIRST AMENDMENT TO SECURITIES PURCHASE AND EXCHANGE AGREEMENT, dated as of March 4, 2025 (this “First Amendment”), is an amendment to that certain Securities Purchase and Exchange Agreement (the “Agreement”) dated as of February 13, 2025, by and among Plus Therapeutics, Inc., a Delaware corporation (the “Compan |
|
| March 4, 2025 |
EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| March 4, 2025 |
Form of Registration Rights Agreement, dated as of March 4, 2025 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 4, 2025, by and among Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and the parties signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to that certain Securities Purchase Agre |
|
| February 18, 2025 |
EX-10.2 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV |
|
| February 18, 2025 |
EX-10.4 Exhibit 10.4 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of February 13, 2025 (this “Agreement”), is among Plus Therapeutics, Inc., a Delaware corporation (the “Company”), CNSide Diagnostics LLC, a Delaware limited liability company (“CNSide”), and each other Subsidiary of the Company which shall become a party to this Agreement by execution and delivery of the form annexed hereto |
|
| February 18, 2025 |
EX-10.5 Exhibit 10.5 SUBSIDIARY GUARANTY 1. Identification. This Guaranty (the “Guaranty”), dated as of February 13, 2025 is entered into by and among CNSide Diagnostics, LLC, a Delaware limited liability company (“Guarantor”), and the lenders identified on Schedule A hereto (each a “Lender” and collectively, “Lenders”). 2. Recitals. 2.1 Guarantor is a direct or indirect subsidiary of Plus Therape |
|
| February 18, 2025 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 18, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 18, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280061 PROSPECTUS SUPPLEMENT NO. 6 (To Prospectus dated June 24, 2024) Plus Therapeutics Inc. This prospectus supplement updates and supplements the prospectus, dated June 24, 2024 (as supplemented to date, the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280061). This prospectus supplement is being filed |
|
| February 18, 2025 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissi |
|
| February 18, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AND EXCHANGE AGREEMENT (NOTES) This Securities Purchase and Exchange Agreement (this “Agreement”) is dated as of February 13, 2025, by and among Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WH |
|
| February 18, 2025 |
EX-10.7 EXHIBIT 10.7 SECOND AMENDMENT TO SECURITIES PURCHASE AGREEMENT This SECOND AMENDMENT TO SECURITIES PURCHASE AGREEMENT, dated as of February 13, 2025 (this “Second Amendment”), is an amendment to that certain Securities Purchase Agreement (the “Agreement”) dated as of May 5, 2024, as previously amended on May 8, 2024, between Plus Therapeutics, Inc., a Delaware corporation (the “Company”), |
|
| February 18, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 18, 2025 |
Exhibit 10.6 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 13, 2025, by and among Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and the parties signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Company and the Purchasers are parties to that certain |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS |
|
| November 14, 2024 |
Certification of Elimination of the Series F Preferred Stock of Plus Therapeutics, Inc Exhibit 3.10 CERTIFICATE OF ELIMINATION of SERIES F PREFERRED STOCK of PLUS THERAPEUTICS, INC. Pursuant to Section 151(g) of the Delaware General Corporation Law Plus Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: FIRST: That pursuant to the authority vested in the Bo |
|
| November 14, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280061 PROSPECTUS SUPPLEMENT NO. 5 (To Prospectus dated June 24, 2024) Plus Therapeutics, Inc. This prospectus supplement updates and supplements the prospectus, dated June 24, 2024 (as supplemented to date, the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280061). This prospectus supplement is being file |
|
| November 14, 2024 |
Exhibit 99.1 Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReSPECT-GBM Trial Data at the 2024 Congress of Neurological Surgeons Annual Conference Establish |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 1, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280061 PROSPECTUS SUPPLEMENT NO. 4 (To Prospectus dated June 24, 2024) Plus Therapeutics Inc. This prospectus supplement updates and supplements the prospectus, dated June 24, 2024 (as supplemented to date, the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280061). This prospectus supplement is being filed |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissio |
|
| October 4, 2024 |
As filed with the Securities and Exchange Commission on October 4, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on October 4, 2024 Registration No. |
|
| October 4, 2024 |
EX-4.11 Exhibit 4.11 INDENTURE DATED AS OF , 20 BETWEEN PLUS THERAPEUTICS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.04 |
|
| October 4, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Plus Therapeutics, Inc. |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissi |
|
| September 6, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280061 PROSPECTUS SUPPLEMENT NO.3 (To Prospectus dated June 24, 2024) Plus Therapeutics Inc. This prospectus supplement updates and supplements the prospectus, dated June 24, 2024 (as supplemented to date, the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280061). This prospectus supplement is being filed |
|
| August 23, 2024 |
Fourth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan. Exhibit 99.1 FOURTH AMENDED AND RESTATED PLUS THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN Adopted by the Board of Directors on April 30, 2020 Approved by the Stockholders on June 16, 2020 Amended and Restated by the Board of Directors on March 22, 2021 Approved by the Stockholders on May 17, 2021 Further Amended and Restated by the Board of Directors on March 28, 2022 Approved by the Stockholders |
|
| August 23, 2024 |
Exhibit 107 Calculation of Filing Fee Table S-8 (Form Type) PLUS THERAPEUTICS, INC. |
|
| August 23, 2024 |
As filed with the Securities and Exchange Commission on August 23, 2024 As filed with the Securities and Exchange Commission on August 23, 2024 Registration No. |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission |
|
| August 15, 2024 |
Plus Therapeutics Inc. Up to 10,774,596 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-280061 PROSPECTUS SUPPLEMENT NO. 2 (To Prospectus dated June 24, 2024) Plus Therapeutics Inc. Up to 10,774,596 Shares of Common Stock This prospectus supplement updates and supplements the prospectus, dated June 24, 2024 (as supplemented to date, the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280061). T |
|
| August 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2024 |
Form of Series B Warrant (May 2024, as amended and restated August 2024) EXHIBIT 4.6 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 14, 2024 |
EXHIBIT 4.8 AMENDMENT AND RESTATEMENT OF THE PLUS THERAPEUTICS, INC. SERIES B COMMON STOCK PURCHASE WARRANT This Amendment and Restatement (this “Amendment”), dated as of August 9, 2024 (the “Effective Date”), is made and entered into by and between Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”) and amends the Series B Common Stock Purchase Warrant to purch |
|
| August 14, 2024 |
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases Presented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trial Management to host conference call August 14, 2024 at 5:00 p. |
|
| August 14, 2024 |
Plus Therapeutics Inc. Up to 10,774,596 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-280061 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated June 24, 2024) Plus Therapeutics Inc. Up to 10,774,596 Shares of Common Stock This prospectus supplement updates and supplements the prospectus, dated June 24, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280061). This prospectus supplement |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAP |
|
| August 14, 2024 |
Form of Series A Warrant (May 2024, as amended and restated August 2024) EXHIBIT 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 14, 2024 |
EXHIBIT 4.7 AMENDMENT AND RESTATEMENT OF THE PLUS THERAPEUTICS, INC. SERIES A COMMON STOCK PURCHASE WARRANT This Amendment and Restatement (this “Amendment”), dated as of August 9, 2024 (the “Effective Date”), is made and entered into by and between Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”) and amends the Series A Common Stock Purchase Warrant to purch |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 10, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| June 24, 2024 |
As filed with the Securities and Exchange Commission on June 24, 2024 S-1/A Table of Contents As filed with the Securities and Exchange Commission on June 24, 2024 Registration No. |
|
| June 24, 2024 |
Up to 10,774,596 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280061 PROSPECTUS Up to 10,774,596 Shares of Common Stock This prospectus relates to up to an aggregate of 10,774,596 shares of common stock, par value $0.001, of Plus Therapeutics, Inc., a Delaware corporation (“Plus Therapeutics,” “Plus,” “we,” “us” or “our”), which may be offered for sale from time to time by selling stockh |
|
| June 20, 2024 |
Plus Therapeutics, Inc. 4200 Marathon Blvd., Suite 200 Austin, TX 78756 Plus Therapeutics, Inc. 4200 Marathon Blvd., Suite 200 Austin, TX 78756 June 20, 2024 VIA EDGAR Mr. Tyler Howes Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-280061 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act |
|
| June 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Plus Therapeutics, Inc. |
|
| June 7, 2024 |
Third Amendment to the 2015 New Employee Incentive Plan EXHIBIT 10.15 THIRD AMENDMENT TO THE PLUS THERAPEUTICS, INC. 2015 NEW EMPLOYEE INCENTIVE PLAN June 6, 2024 This Third Amendment amends the 2015 New Employee Incentive Plan (as amended, the “Plan”) of Plus Therapeutics, Inc., a Delaware corporation (the “Company”). Unless otherwise specifically defined herein, each capitalized term used herein shall have the meaning afforded such term under the Pla |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 7, 2024 |
Power of Attorney (included on the signature page hereto). As filed with the Securities and Exchange Commission on June 7, 2024 Registration No. |
|
| June 5, 2024 |
PSTV / Plus Therapeutics, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Plus Therapeutics, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 72941H509 (CUSIP Number) May 9, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ☐ Rule |
|
| June 4, 2024 |
Lending Agreement, dated April 5, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC EX-10.1 Exhibit 10.1 LoanAdvanceTM Lending Agreement KEEP A COPY FOR YOUR RECORDS. This is your LoanAdvance Lending Agreement with Pershing LLC (“Pershing”). TO: Pershing LLC In consideration of your accepting and carrying for the undersigned one or more accounts introduced to you by my broker, bank, or other introducing firm (“Introducing Firm”), which Introducing Firm is intended to have the ben |
|
| June 4, 2024 |
Extension of Credit, dated May 29, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC EX-10.3 Exhibit 10.3 Statement of Purpose for an Extension of Credit by a Creditor (Federal Reserve Form T–4) Name of Creditor: Pershing LLC • OMB No. 7100-0019 • Approval expires June 30, 2024 This form is required by law (15 U.S.C. 78g and 78w; 12 CFR 220). The Federal Reserve may not conduct or sponsor, and an organization (or a person) is not required to respond to, a collection of information |
|
| June 4, 2024 |
EX-10.2 Exhibit 10.2 LoanAdvanceTM Interest Rate Form STEP 1. ACCOUNT INFORMATION Non-Purpose Loan Account Number 3ZT047968 STEP 2. INTEREST RATE ACKNOWLEDGEMENT The undersigned (“Borrower”) has executed a LoanAdvance Lending Agreement (the “Agreement”) with Pershing LLC (“Pershing”). Pursuant to which Borrower has access to a line of credit collateralized by the value of securities held in Bo |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 20, 2024 |
Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERA |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 15, 2024 |
Exhibit 99.1 Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive to |
|
| May 9, 2024 |
EX-4.1 EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2024 PLUS THERAPUETICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2024 |
EX-10.3 EXHIBIT 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 5, 2024, by and among Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and the parties signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to that certain Securities Purchas |
|
| May 9, 2024 |
EX-10.2 EXHIBIT 10.2 FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT This FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT, dated as of May 8, 2024 (this “First Amendment”), is an amendment to that certain Securities Purchase Agreement (the “Agreement”) dated as of May 5, 2024, between Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature |
|
| May 9, 2024 |
EX-10.1 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 5, 2024, between Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| May 9, 2024 |
Form of Series A Common Warrant. EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 9, 2024 |
Form of Series B Common Warrant. EX-4.3 EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 8, 2024 PLUS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| March 13, 2024 |
EX-99.1 Exhibit 99.1 Corporate Presentation March 2024 Forward Looking Statement This presentation contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this presentation other than statements of historical fact are forward-looki |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 12, 2024 PLUS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation or Organizati |
|
| March 8, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Plus Therapeutics, Inc. |
|
| March 8, 2024 |
As filed with the Securities and Exchange Commission on March 8, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 8, 2024 Registration No. |
|
| March 5, 2024 |
Exhibit 99.1 Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached agreement to expand ReSPECT-GBM Phase 2 trial and add new sites Current financial forecast |
|
| March 5, 2024 |
Incentive Compensation Recovery Policy Exhibit 97.1 Plus Therapeutics, Inc. Incentive Compensation Recovery Policy The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best interests of the Company and its stockholders and essential to the Company’s success. The Board is adopting this Incen |
|
| March 5, 2024 |
Exhibit 10.16 TENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS TENTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is made effective as of June 28, 2023 (the “Amendment Date”) and made, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; |
|
| March 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2024 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTI |
|
| November 22, 2023 |
1,300,000 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No.333-275531 1,300,000 Shares of Common Stock This prospectus relates to the offer and sale of up to 1,300,000 shares of our common stock, par value $0.001 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock to which this prosp |
|
| November 22, 2023 |
As filed with the Securities and Exchange Commission November 22, 2023 S-1 Table of Contents As filed with the Securities and Exchange Commission November 22, 2023 Registration No. |
|
| November 22, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Plus Therapeutics, Inc. |
|
| November 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissi |
|
| November 20, 2023 |
Exhibit 99.1 Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients re |
|
| November 17, 2023 |
PLUS THERAPEUTICS, INC. 4200 Marathon Blvd. Suite 200 Austin, TX 78756 PLUS THERAPEUTICS, INC. 4200 Marathon Blvd. Suite 200 Austin, TX 78756 November 17, 2023 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-275531) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General R |
|
| November 14, 2023 |
Power of Attorney (see signature page) S-1 Table of Contents As filed with the Securities and Exchange Commission November 14, 2023 Registration No. |
|
| November 14, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Plus Therapeutics, Inc. |
|
| October 31, 2023 |
Exhibit 99.1 Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights New survival data from 15 patients in the Phase 2 ReSPECT-GBM trial of rhenium (186Re) obisbemeda in recurrent glioblastoma (rGBM) will be presented at SNO Annual Meeting on November 17th; Company will also host a Key Opinion Leader (KOL) event following the meeting to discuss the results Completed |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissio |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS T |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissio |
|
| August 21, 2023 |
1,500,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No.333-273823 1,500,000 Shares of Common Stock This prospectus relates to the offer and sale of up to 1,500,000 shares of our common stock, par value $0.001 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock to which this prospectus |
|
| August 16, 2023 |
PLUS THERAPEUTICS, INC. 4200 Marathon Blvd. Suite 200 Austin, TX 78756 PLUS THERAPEUTICS, INC. 4200 Marathon Blvd. Suite 200 Austin, TX 78756 August 16, 2023 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-273823) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rul |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAP |
|
| August 14, 2023 |
Exhibit 99.1 Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights ReSPECT clinical trial data continues to demonstrate promise for treatment of leptomeningeal metastases and recurrent glioblastoma Received FDA approval to move into Phase 1/Part B of the ReSPECT-LM clinical trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, August 14, 20 |
|
| August 14, 2023 |
Tenth Amendment to Loan and Security Agreement Exhibit 10.2 TENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS TENTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is made effective as of June 28, 2023 (the “Amendment Date”) and made, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; a |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 9, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Plus Therapeutics, Inc. |
|
| August 9, 2023 |
As filed with the Securities and Exchange Commission August 9, 2023 S-1 Table of Contents As filed with the Securities and Exchange Commission August 9, 2023 Registration No. |
|
| May 16, 2023 |
Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements EX-99.1 Exhibit 99.1 Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) – Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that it has received notification from T |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 28, 2023 |
Plus Therapeutics Announces Reverse Stock Split EX-99.1 Exhibit 99.1 Plus Therapeutics Announces Reverse Stock Split AUSTIN, Texas, April 28, 2023 – Plus Therapeutics, Inc. (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of co |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2023 |
Certificate of Amendment to Amended and Restated Certificate. EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PLUS THERAPEUTICS, INC. Plus Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: The name of the corporation is Plus Therapeutics, Inc. (the “Corporation”). SECOND: On February 24, 2023, the |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 21, 2023 |
Plus Therapeutics, Inc. 2020 Stock Incentive Plan, as further amended and restated Exhibit 10.1 PLUS THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN Adopted by the Board of Directors on April 30, 2020 Approved by the Stockholders on June 16, 2020 Amended and Restated by the Board of Directors on March 22, 2021 Approved by the Stockholders on May 17, 2021 Further Amended and Restated by the Board of Directors on March 28, 2022 Approved by the Stockholders on May 16, 2022 Further Ame |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 20, 2023 |
Exhibit 99.1 Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights Plus completes Phase 1/Part A of the ReSPECT-LM trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, April 20, 2023 – Plus Therapeutics, Inc.(Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform t |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERA |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 7, 2023 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Pro |
|
| March 3, 2023 |
Certificate of Designation of Series F Preferred Stock, dated March 3, 2023 EX-3.1 Exhibit 3.1 PLUS THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF SERIES F PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Plus Therapeutics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board |
|
| March 3, 2023 |
EX-10.1 3 d449434dex101.htm EX-10.1 Exhibit 10.1 Plus Therapeutics, Inc. Series F Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENT THIS AGREEMENT, dated as of March 3, 2023, is by and between Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 PLUS THERAPEUTICS, INC. |
|
| February 24, 2023 |
PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTI |
|
| February 23, 2023 |
Exhibit 99.1 Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers Awarded $17.6 million Cancer Prevention & Research Institute of Texas (CPRIT) grant to support clinical development of rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Cash, grant funding, and di |
|
| February 13, 2023 |
PSTV / Plus Therapeutics Inc / Parkman Healthcare Partners LLC Passive Investment SC 13G/A 1 d992959213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Plus Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 72941H400 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissio |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissi |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS T |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 20, 2022 |
Exhibit 99.1 Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM) Completed cGMP manufacturing objectives to support Phase 2 clinical trials for 186RNL Initiating ReSPECT-GBM Phase 2 t |
|
| September 22, 2022 |
Exhibit 10.1 [***] Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission. DP220039 Andrew Sims STATE OF TEXAS COUNTY OF TRAVIS This CANCER RESEARCH GRANT CONTRACT (?Contract?) is by and between the Cancer Prevention and Research Institute of Texas (?CPRIT?), hereinafter referred |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commiss |
|
| September 22, 2022 |
Exhibit 99.1 Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support majority of 186RNL targeted therapeutic development costs for leptomeningeal metastases program over three years; extends expected Company cash runway through 2025 AU |
|
| September 9, 2022 |
$5,000,000 Plus Therapeutics, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-249410 PROSPECTUS SUPPLEMENT (To Prospectus dated October 19, 2020) $5,000,000 Plus Therapeutics, Inc. Common Stock We entered into a sales agreement with Canaccord Genuity LLC, or Canaccord, on September 9, 2022, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In a |
|
| September 9, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissi |
|
| September 9, 2022 |
Exhibit 1.1 PLUS THERAPEUTICS, INC. EQUITY DISTRIBUTION AGREEMENT September 9, 2022 CANACCORD GENUITY LLC 99 High Street Boston, Massachusetts 02110 Ladies and Gentlemen: As further set forth in this agreement (this ?Agreement?), Plus Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell from time to time through Canaccord Genuity LLC (the ?Agent?), as sales agent, |
|
| August 18, 2022 |
9,500,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-266684 9,500,000 Shares of Common Stock This prospectus relates to the offer and sale of up to 9,500,000 shares of our common stock, par value $0.001 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock to which this prospectus |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission |
|
| August 15, 2022 |
United States securities and exchange commission logo August 15, 2022 Andrew Sims Chief Financial Officer Plus Therapeutics, Inc. |
|
| August 15, 2022 |
PLUS THERAPEUTICS, INC. 4200 Marathon Blvd. Suite 200 Austin, TX 78756 CORRESP 1 filename1.htm PLUS THERAPEUTICS, INC. 4200 Marathon Blvd. Suite 200 Austin, TX 78756 August 15, 2022 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-266684) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rul |
|
| August 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Plus Therapeutics, Inc. |
|
| August 9, 2022 |
As filed with the Securities and Exchange Commission August 8, 2022 Table of Contents As filed with the Securities and Exchange Commission August 8, 2022 Registration No. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2022 |
Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (the ?Agreement?), dated as of August 2, 2022, by and between PLUS THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). Capitalized terms used herein and not otherwise defined are defined in Section 1 of this Agreement. WHEREAS: Subject to the terms |
|
| August 8, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of August 2, 2022, by and between PLUS THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the ?Buyer?). Capitalized terms used herein and not otherwise defined herein shall have |
|
| July 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34375 (Commission File Number) |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ?QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPE |
|
| July 21, 2022 |
Exhibit 99.1 Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases On track to complete key manufacturing objectives for cGMP 186RNL to support ongoing and planned clinical trials in 2022 and beyond Multiple planned data presentations for gliobla |
|
| May 27, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 20, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34375 (Commission File Number) |
|
| May 20, 2022 |
Plus Therapeutics, Inc. 2020 Stock Incentive Plan, as amended Exhibit 10.1 PLUS THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN Adopted by the Board of Directors on April 30, 2020 Approved by the Stockholders on June 16, 2020 Amended and Restated by the Board of Directors on March 22, 2021 Approved by the Stockholders on May 17, 2021 Further Amended and Restated by the Board of Directors on March 28, 2022 Approved by the Stockholders on May 16, 2022 - i - Table |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ?QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAP |
|
| April 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34375 (Commission File Number |
|
| April 21, 2022 |
Exhibit 99.1 Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for leptomeningeal metastases Closed in licensing transaction for novel targeted radioembolic technology for the treatment of solid organ tumors Expanded ReSPECT-GBM clinical trial partnership with Medidata to design innova |
|
| April 21, 2022 |
Exhibit 10.1 ***Certain identified information has been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission because it is both (i) not material to investors and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (?[***]?) in this exhibit*** EXECUTION Medidata Services Agreement This |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 7, 2022 |
DEF 14A 1 pstv-def14a20220516.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 5, 2022 |
Exhibit 99.1 Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership Companies collaborate to design innovative registrational trial of 186RNL for recurrent glioblastoma Proprietary Synthetic Control Arm? solution intended to enhance enrollment and reduce costs AUSTIN, Texas, April 5, 2022 ? Plus Therapeutics, Inc. (Nasdaq: PSTV) (the ?Company?), a clinical-stage pharmaceutical |
|
| April 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34375 (Commission File Number |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| February 24, 2022 |
Exhibit 99.1 Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights Expanded pipeline with recently licensed targeted interventional radiotherapeutics platform Announced positive interim data from ReSPECT-GBM Phase 1 clinical trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, February 24, 2022 ? Plus Therapeutics, Inc. (Nasd |
|
| February 24, 2022 |
Form of Notice of Grant and Stock Option Agreement under the 2020 Stock Incentive Plan. Exhibit 10.26 PLUS THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT You have been granted the following Option (this ?Option? or this ?Award?) to purchase Common Stock of PLUS THERAPEUTICS, INC. (the ?Company?) under the Company?s 2020 Stock Incentive Plan, as amended and restated (the ?Plan?): Name of Optionee: Total Number of Option Shares Granted: Type of Option: Exerci |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34375 (Commission File Num |
|
| February 24, 2022 |
Execution Copy Exhibit 10.2 ***Certain identified information has been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission because it is both (i) not material to investors and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (?[***]?) in this exhibit*** PATENT & Technology LICENSE |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTI |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Plus Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 72941H400 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 4, 2022 |
PSTV / Plus Therapeutics Inc / Hudson Bay Capital Management LP - PSTV 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Plus Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 72941H400 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 4, 2022 |
PSTV / Plus Therapeutics Inc / Parkman Healthcare Partners LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 14, 2022 |
EX-1.1 2 d656440dex11.htm EX-1.1 Exhibit 1.1 PLUS THERAPEUTICS, INC. EQUITY DISTRIBUTION AGREEMENT January 14, 2022 CANACCORD GENUITY LLC 99 High Street Boston, Massachusetts 02110 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Plus Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Canaccord Genuity LL |
|
| January 14, 2022 |
$5,000,000 Plus Therapeutics, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-249410 PROSPECTUS SUPPLEMENT (To Prospectus dated October 19, 2020) $5,000,000 Plus Therapeutics, Inc. Common Stock We entered into a sales agreement with Canaccord Genuity LLC, or Canaccord, on January 14, 2022, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In ac |
|
| January 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2022 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissio |
|
| January 6, 2022 |
Exhibit 99.1 Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline Licenses targeted interventional radiotherapeutics platform Worldwide exclusive rights obtained for patents and next-generation technology to deliver targeted, precision radiotherapeutics for solid organ cancers Initial IND submission for treatment of liver cancer planned in 2022 AUSTIN, Texas, January 6, 2 |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissi |
|
| November 18, 2021 |
Exhibit 99.1 Plus Therapeutics Announces Positive Interim Data from ReSPECT?-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting Latest interim analysis shows Rhenium-186 NanoLiposome (186RNL) well-tolerated without dose-limiting toxicities Mean and median overall survival in patients receiving absorbed dose greater than 100 Gy is 453.8 days and 330 days, respectively, |
|
| November 18, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissi |
|
| October 21, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34375 (Commission File Numb |
|
| October 21, 2021 |
Exhibit 99.1 Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, October 21, 2021 ? Plus Therapeutics, Inc. (Nasdaq: PSTV) (the ?Company?), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financ |
|
| October 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ?QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS TH |
|
| September 21, 2021 |
Amended and Restated Bylaws of Plus Therapeutics, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF PLUS THERAPEUTICS, INC. (As of September 15, 2021) TABLE OF CONTENTS Page ARTICLE 1 Offices 4 1.1???Registered Office 4 1.2???Other Offices 4 ARTICLE 2 Meeting of Stockholders 4 2.1???Place of Meeting 4 2.2???Annual Meeting 4 2.3???Advance Notice of Business to be Brought before a Meeting 5 2.4???Advance Notice of Nominations for Election of Directors at |
|
| September 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commiss |
|
| September 21, 2021 |
Certificate of Elimination of Series A Preferred Stock. Exhibit 3.2 CERTIFICATE OF ELIMINATION OF THE SERIES A 3.6% CONVERTIBLE PREFERRED STOCK OF PLUS THERAPEUTICS, INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware (the ?DGCL?), it is hereby certified that: 1. The name of the company (hereinafter referred to as the ?Company?) is Plus Therapeutics, Inc. 2. The designation of the series of shares of stock of the Com |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2021 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34375 33-0827593 (State or other jurisdiction of incorporation) (Commissi |
|
| September 13, 2021 |
Employment Agreement between Norman LaFrance and Plus Therapeutics, Inc. Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into by and between Plus Therapeutics, Inc., a Delaware corporation (the ?Company?), and Norman LaFrance, M.D. (?Executive?), and shall be effective on the Executive?s start date of December 8, 2021 (the ?Effective Date?). WHEREAS, the Company desires to employ Executive, and Executive desires to be employed |
|
| September 13, 2021 |
Exhibit 99.1 Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company?s Chief Medical Officer AUSTIN, Texas, September 13, 2021 ? Plus Therapeutics, Inc. (Nasdaq: PSTV) (the ?Company?), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the appointment of No |
|
| September 10, 2021 |
5,865,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-259325 PROSPECTUS 5,865,000 Shares of Common Stock This prospectus relates to the offer and sale of up to 5,865,000 shares of our common stock, par value $0.001 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock to which this |
|
| September 8, 2021 |
PLUS THERAPEUTICS, INC. 4200 Marathon Blvd. Suite 200 Austin, TX 78756 PLUS THERAPEUTICS, INC. 4200 Marathon Blvd. Suite 200 Austin, TX 78756 September 8, 2021 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-259325) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General R |
